A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients

Conditions: Overall Response Rate Interventions: Drug: Combination of Cardonizumab with Lenvatinib and SOX regimen Sponsors: Fujian Medical University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials